Text generated with AI support and subjected to deterministic data and consistency checks before publication.
The second quarter of 2026 delivered $15 billion of revenue, up 3% as reported and about 1% operationally, while launched and acquired products grew 18% operationally.
was $3.5 billion in the first six months of 2026. Pfizer also recorded $4.3 billion of non-cash intangible-asset impairments in the quarter, an important sign that some acquired-asset forecasts had weakened.
The key operating issue is whether new products can replace revenue from medicines facing loss of exclusivity.
Successful pipeline approvals, acquisitions, and sustained adoption would protect revenue and cash. Weaker replacement would pressure both while research spending continues.
Pfizer discovers, develops, manufactures, markets, and distributes medicines and vaccines worldwide. It sells mainly through wholesalers and also supplies retailers, hospitals, clinics, government agencies, and pharmacies. Insurers and other healthcare payers influence demand through formularies and rebate contracts. Its economic engine is a medicine portfolio whose established products generate cash while new products replace revenue lost when loss of exclusivity allows competition.
Biopharma is Pfizer’s only reportable segment and contains its medicine and vaccine portfolio, including cardiovascular treatment Eliquis and vaccines such as Prevnar. PC1 provides contract development and manufacturing services and specialty active pharmaceutical ingredients. Pfizer Ignite provided strategic guidance and end-to-end research and development services to selected biotechnology companies. Pfizer is winding it down.
Management is prioritizing the product pipeline, marketed brands, research milestones, and business development, including acquisitions and licensing. The decisive dependency is portfolio replacement: research productivity, clinical approvals, product adoption, acquired revenue retention, integration, and operating returns must offset patent-related declines. That future replacement record will determine whether Pfizer’s established cash engine remains durable.
Create a free account to unlock the rest of this report and access all published research.